Lilly scores early positive data for new JAK drug
Source ↗
👁 1
💬 0
Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.
Comments (0)